Original Article

Anti-proliferative and Anti-angiogenic Effects of CB₂R Agonist (JWH-133) in Non-small Lung Cancer Cells (A549) and Human Umbilical Vein Endothelial Cells: an in Vitro Investigation

B. VIDINSKÝ¹, P. GÁL²,³,⁵, M. PILÁTOVÁ¹, Z. VIDOVÁ¹,³, P. SOLÁR⁴, L. VARINSKÁ¹, L. IVANOVÁ¹, J. MOJŽIŠ¹

¹Department of Pharmacology, Pavol Jozef Šafárik University, Košice, Slovak Republic
²Department of Pathological Anatomy, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic
³1st Department of Psychiatry, Louis Pasteur University Hospital and Pavol Jozef Šafárik University, Košice, Slovak Republic
⁴Institute of Biology and Ecology, Pavol Jozef Šafárik University, Košice, Slovak Republic
⁵East-Slovak Institute of Cardiovascular Diseases, Department for Biomedical Research, Košice, Slovak Republic
⁶Institute of Histology and Embryology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic

Received July 12, 2011. Accepted August 17, 2011.

This study was supported by the Slovak Research and Development Agency (No. APVV-0325-07) and by the Slovak Grant Agency for Science (No. VEGA-1/4236/07).

Corresponding author: Peter Gál, East-Slovak Institute of Cardiovascular Diseases, Department for Biomedical Research, Ondavská 8, 040 11 Košice, Slovak Republic. e-mail: galovec@yahoo.com or pgal@vusch.sk


Folia Biologica (Praha) 58, 75-80 (2012)

Abstract. Non-small cell lung cancer has one of the highest mortality rates among cancer-suffering patients. It is well known that the unwanted psychotropic effects of cannabinoids (CBs) are mediated via the CB₁ receptor (R), and selective targeting of the CB₂R would thus avoid side effects in cancer treatment. Therefore, the aim of our study was to evaluate the effect of selective CB₂R agonist, JWH-133, on A549 cells (non-small lung cancer) and human umbilical vein endothelial cells (HUVECs). Cytotoxicity assay and DNA fragmentation assay were employed to evaluate the influence of JWH-133 (3-(1,1-dimethylbutyl)-1-deoxy-Δ⁸-tetrahydrocannabinol) on investigated cancer cells. In addition, migration assay and gelatinase zymography were performed in HUVECs to assess JWH-133 anti-angiogenic activity. Our study showed that JWH-133 exerted cytotoxic effect only at the highest concentration used (10⁻⁴ mol/l), while inhibition of colony formation was also detected at the non-toxic concentrations (10⁻⁵–10⁻⁸ mol/l). JWH-133 was also found to be able to induce weak DNA fragmentation in A549 cells. Furthermore, JWH-133 at non-toxic concentrations inhibited some steps in the process of angiogenesis. It significantly inhibited endothelial cell migration after 17 h of incubation at concentrations of 10⁻⁴–10⁻⁵ mol/l. In addition, JWH-133 inhibited MMP-2 secretion as assessed by gelatinase zymography. The present study demonstrates the in vitro anti-proliferative and anti-angiogenic potential of CB₂R agonist, JWH-133, in non-small lung cancer cells and HUVECs. Our results generate a rationale for further in vivo efficacy studies with this compound in preclinical cancer models.

Introduction

Non-small cell lung cancer is one of the leading causes of cancer deaths worldwide (Preet et al., 2011). In spite of this fact, only limited therapeutic options are available in the current clinical practice. Although the first anticancer effect of cannabinoids (CBs) was shown in the 1970s (Grotenhermen, 2005), their use in modern medicine has remained controversial until today. The revolution in CB research started when the endocannabinoid system (ECS) was discovered followed by cloning of G-protein-coupled CB receptors (CBR), CB_R in 1990 (Matsuda et al., 1990) and CB₂R three years later (Munro et al., 1993). CB₂R is expressed mainly in the central nervous system (CNS) and mediates all psycho-
active effects of cannabinoids, whereas CB$_R$ is localized in the periphery and has no psychoactive effects (Rodríguez de Fonseca et al., 2005).

Since cloning of the CB receptors the influence of their modulators on tumour cell proliferation has started to be investigated more intensively. Numerous studies have been published describing both anti- and pro-cancer effects of CBs (Vidinsky et al., 2006). At present, the medications based on CBs are registered as useful adjuvants to conventional anti-tumour chemotherapy (Sarfaraz et al., 2008). However, still more studies point to the anti-proliferative effects of CBs on tumour cells (Bifulco et al., 2006).

It is well known that the unwanted psychotropic effects of CBs are mediated via the CB$_1$R. From this point of view, selective targeting of CB$_R$ would avoid side effects in cancer treatment. This study was, therefore, aimed at assessing the effect of highly selective CB$_R$ agonist, JWH-133 (3-(1,1-dimethylbutyl)-1-deoxy-Δ8-tetrahydrocannabinol), on non-small lung cancer cells and on human umbilical vein endothelial cells, in which the expression of this receptor has previously been confirmed (Schley et al., 2009; Preet et al., 2011).

Material and Methods

**JWH-133**

JWH-133 (99 % purity determined by GLC) was a kind gift of Prof. J.W. Huffman (Clemson University, Clemson, SC).

**A549 non-small lung cancer cells**

A549 cells were kindly provided by Dr. M. Hajdúch (Palacký University, Olomouc, Czech Republic). Cells were routinely maintained in RPMI 1640 medium with Glutamax-I supplemented with 10% foetal calf serum, penicillin (100 IU/ml) and streptomycin (100 µg/ml) (all from Invitrogen, Grand Island, NY) in the atmosphere of 5% CO$_2$ in humified air at 37 °C. Cell viability, estimated by trypan blue (Sigma-Aldrich, St. Louis, MO) exclusion, was greater than 95 % prior to each experiment.

**Isolation and in vitro cultivation of HUVECs**

HUVECs were isolated, cultured, and characterized as previously described (van Hinsbergh et al., 1987; Defilippi et al., 1991). Cells were cultured on gelatin-coated dishes in cM199 (M199 medium supplemented with 10 % human serum, 10 % heat-inactivated newborn calf serum (NBCS) (all from Invitrogen), 150 µg/ml crude endothelial cell growth factor (ECGF), 5 U/ml heparin, 100 IU/ml penicillin, and 100 µg/ml streptomycin, all from Cambrex (Verviers, Belgium) at 37 °C under 5 % CO$_2$/95 % air atmosphere.

**Colony formation assay**

For colony formation assay, A459 cells were seeded in six-well plates at a density of 1,000 cells per well and allowed to adhere for 10 h before treatment. Culture medium containing variable concentrations of JWH-133 was added to the cells and incubated for 14 days. The cells were then fixed in buffered formalin (pH 7.2) and stained with 0.01 % crystal violet. The crystal violet stain was then extracted with 10% acetic acid for 60 min and read at 540 nm. Cell survival at each drug concentration was expressed as a percentage of survival of controls (no drug added).

**Cytotoxicity assay (MTT)**

The cytotoxic effects of the tested compounds were studied by using colorimetric microculture assay with the 3-(dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) endpoint. In this assay, the amount of MTT reduced to formazan is proportional to the number of viable cells (Mosmann, 1983; Nowakowska et al., 2010). Briefly, the cells (1 × 10$^4$ cells per well) were plated in 96-well polystyrene microplates (Sarstedt, Nümbrecht, Germany) in the culture medium containing the tested chemicals at final concentrations 10$^{-4}$–10$^{-9}$ mol/l. After 72 h of incubation, 10 µl of MTT (5 mg.ml$^{-1}$) (Sigma-Aldrich) were added into each well. After additional 4 h, during which insoluble formazan was produced, 100 µl of 10% sodium dodecyl sulphate were added into each well and another 12 h were allowed for the formazan to be dissolved. The absorbance was measured at 540 nm using the automated MRX microplate reader (Dynatech Laboratories, West Sussex, UK). The absorbance of the control wells was taken as 100 % and the results were expressed as a percentage of the control.

**DNA fragmentation assay**

Treated (for 72 h) and untreated cells (1 × 10$^6$) were washed twice with 1× PBS, calcium and magnesium free. Lysis of cells was performed in a lysis buffer containing 10 mmol/l TRIS, 10 mmol/l EDTA, 0.5% Triton X-100. Proteinase K (1 mg/ml) was added and the cells were incubated at 37 °C for 1 h. Then they were heated at 70 °C for 10 min, and after adding RNAase (200 µg/ml) the cells were again incubated at 37 °C for 1 h. Samples were transferred to 2% agarose gel and run at 40 V for 3 h. DNA fragments were visualized by a UV illuminator.

**Two dimensional migration (wound healing) assay**

The motility of HUVECs was assayed using wound-healing assay (Martínez-Poveda et al., 2005). Briefly, HUVECs were cultured in a 24-well plate in the cM199 medium to reach confluence. A 2 mm pipette tip was used to wound the monolayer of cells. Afterwards, the medium was replaced with fresh ECGF and human serum-free medium containing the studied compound at different concentrations in the presence of 25 ng/ml of recombinant VEGF-A (Biosource, Camarillo, CA). The wounded area was photographed at the start (t = 0 h) and at time point t = 17 h. Quantification of cell migration was performed as previously described (Cheung and Li, 2002). The percentage of remaining scratched area was
calculated after being marked and quantified by the histogram function of the Adobe Photoshop 5.5 software (Adobe Systems Incorporated, CA). The experiments were performed in duplicate wells and repeated three times.

**Gelatinase zymography**

Gelatinolytic activities of secreted matrix metalloproteinases (MMPs) were analysed by zymography on gelatin-containing polyacrylamide gels as previously described (Newcomb et al., 2005). Using this technique both active and latent species can be visualized.

Media were obtained by incubating cells in 10 cm² dishes for 48 h with 1 ml of serum-free cultivation medium to which appropriate concentration of JWH-133 was added. Phorbol 12-myristate 13-acetate was used as a positive control. The conditioned media were centrifuged for 20 min at 1000 g in a microfuge to remove cells and cellular debris, and samples were frozen at -80 °C until use. Samples were placed into the buffer containing 3% (w/v) SDS and 10% (w/v) glycerol and then applied to 10% (w/v) polyacrylamide gels co-polymerized with 2 mg/ml gelatin. After electrophoresis the gels were renatured in 2.5 % Triton X-100 (2 × 15 min), then incubated overnight at 37 °C in development buffer (50 mM Tris-HCl, pH 7.6; 10 mM CaCl₂; 50 mM NaCl; 0.05 % Brij35 [MP Biomedicals]). Gels were stained with 0.5 % Coomassie Brilliant Blue R-250 in 50% methanol and 10% acetic acid for 40 min at room temperature and then destained for 1 h in 50% methanol and 10% acetic acid. Data from three independent experiments were pooled for statistical analysis.

**Statistical analysis**

For all experiments, mean values and standard deviations (from three experiments) were calculated. To evaluate the statistical significance observed between groups, one-way ANOVA followed by Tukey-Kramer post-hoc test were employed. Significance was considered to be present if P < 0.05.

**Results**

**Colony formation assay**

Compared to the control, JWH-133 significantly inhibited the capacity of producing colonies in both cell lines in all tested concentrations (10⁻⁴–10⁻⁸ mol/l; P < 0.001, P < 0.01). These results thus suggest that cannabinoid treatment is highly effective in suppressing the colony-forming ability of human cancer cells (Fig. 1a).

![Graph showing colony formation assay](image1)

![Graph showing cell viability](image2)

![DNA fragmentation image](image3)

**Fig. 1.** a) Colony formation assay. Cell survival at each drug concentration was expressed as a percentage of survival of controls (no drug added). JWH-133 significantly decreased colony formation in A549 cells; b) Effect of JWH-133 on viability of cancer (A549) and endothelial (HUVEC) cells after 72 h incubation at JWH concentrations 10⁻⁴–10⁻⁸ mol/l detected by MTT test; c) DNA fragmentation of A549 cells after 72 h incubation with JWH 133 at the concentration 10⁻⁴ mol/l. Lanes indicate different treatments: Lane 1 – negative control; Lane 2 – positive control (etoposide 50 μl/ml); Lane 3 – DNA fragmentation after 72 h of incubation with JWH 133.
**MTT assay**

Survival of tumour cells and HUVECs exposed to various concentrations of JWH-133 is shown in Fig. 1b. JWH-133 markedly decreased cell survival at the concentration $10^{-4}$ mol/l in A549 cells and HUVECs.

**DNA fragmentation assay**

The detection of internucleosomal DNA cleavage (DNA laddering) is considered to be an indicator of apoptosis. In our experiments, 72 h of incubation of A549 cells with JWH-133 at a concentration of $10^{-4}$ mol/l led to only weak DNA fragmentation (Fig. 1c).

**Wound healing assay**

After wounding with a pipette tip, solvent controls reformed a confluent monolayer within 24 h of incubation. JWH-133 was added at concentrations of $10^{-4}$–$10^{-8}$ mol/l (concentrations of $10^{-5}$ and $10^{-8}$ mol/l were nontoxic). In the presence of this cannabinoid a potent dose-dependent inhibition of endothelial cell migration was observed at concentrations $10^{-4}$–$10^{-5}$ mol/l ($P < 0.001$) and $10^{-6}$ mol/l ($P < 0.01$) (Fig. 2a, b).

**Gelatinase zymography**

The effect of JWH-133 on MMP-2 expression/activity in HUVECs is shown in Fig. 2c. JWH-133 inhibited enzyme secretion at $10^{-4}$ mol/l. The bands of the standard for MMP-2 reflect both the inactive and the active form of the studied enzyme. We observed only the pro-enzyme of MMP-2 in our samples, not the active form of this enzyme. Therefore, we can claim that JWH-133 treatment decreased the secretion of MMP-2 without inhibiting MMP activity.

**Discussion**

Despite recent advances in the early detection and therapy, lung cancer-related mortality still remains very high (Preet et al., 2011). Surgical removal of the malignancy presents in most of cases the ultimate way for complete remission of the disease (Belák et al., 2010).
Therefore, there is an emerging request for alternative therapies with increased efficacy. For the first time, Munson et al. (1975) reported lung adenocarcinoma growth retardation following oral administration of CBs. Later, it was found that CBs suppressed lung adenocarcinoma growth via inhibition of DNA synthesis (White et al., 1976; Friedman et al., 1977). Another study conducted with A549 cells showed that micromolar concentrations of Δ9-tetrahydrocannabinol are able to increase expression of interferon α (IFN-α) (Berdyshev et al., 1997), an important modulator of anti-tumour immunity (Krejčová et al., 2009). In parallel, we found a significant decrease in A549 cell viability as well as limited DNA fragmentation after treatment with JWH-133.

On the other hand, in experiments with the cancer cell line, more interesting effects of the tested agonist were observed by colony-forming inhibition than by direct cytotoxic effects observed during the MTT assay. JWH-133 significantly reduced the ability of cancer cells to create colonies also at nano-molar concentrations. Since it is well known that solid tumours do not grow as monoclonal tumours but as colonies, our results generate a rationale for in vivo studies with JWH-133 in preclinical animal cancer models.

At the present time, inhibition of angiogenesis in solid tumours is one of the current topics in the area of cancer research and/or treatment (Ferrara and Kerbel, 2005). Previously, it has been shown that a non-selective CBR agonist inhibits angiogenesis (Blazquez et al., 2003, 2004). Accordingly, in our current work we tested the effect of JWH-133 on endothelial cells and found inhibition of cell migration. Moreover, administration of Δ9-tetrahydrocannabinol (THC), a non-selective CBR agonist, down-regulates MMP-2 expression in gliomas generated in mice (Blazquez et al., 2008). In our study we bring new colony formation since we have shown that JWH-133, a selective CB2R agonist, reduces MMP-2 secretion as well.

In conclusion, our study showed that JWH-133, a selective CB2R agonist, displays anti-tumour activity at micro-molar concentrations in A549 cells and down-regulates MMP-2 activity, thus providing novel information on targeting the second cannabinoid receptor. Since JWH-133 is a non-psychoactive agent, further in vivo research should be performed to facilitate its clinical use.

Acknowledgement

There is no conflict of interest.

References


